FY2025 · ended Dec 31, 2025 · Revenue $3.02M, +71.6% YoY · Filed Apr 1, 2026
TherapeuticsMD, Inc. (TXMD) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $3.0 million and a net loss of $569,000. As of Jun 30, 2026 it held $9.2 million in cash and investments and $5.6 million in total debt.
Revenue (TTM)
$3.27M
Net income (TTM)
$-217,000
+52.7% vs year-ago TTM
Operating cash flow (TTM)
$3.10M
+201.9% vs year-ago TTM
Free cash flow
$-142.73M
+10.6% vs prior year
EPS (TTM)
$-0.02
+53.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
11.57M
+0.0% vs prior year
Net cash
$3.63M
as of Jun 30, 2026
Operating margin
-120.9%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TXMD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Boca Raton, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 25743
- Former names
- AMHN, Inc. (until Sep 14, 2011); CROFF ENTERPRISES INC (until Sep 4, 2009); CROFF OIL CO (until Apr 1, 1997)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.0M | $1.8M | $1.3M | $70.0M | $2.6M |
| Operating income | -$4.4M | -$6.1M | -$8.5M | $1.2M | -$79.6M |
| Net income | -$569,000 | -$2.2M | -$10.3M | $112.0M | -$172.4M |
| Diluted EPS | -$0.05 | -$0.19 | -$0.99 | $11.96 | — |
| Operating cash flow | $2.5M | $1.2M | -$23.1M | $9.4M | -$142.7M |
| Free cash flow | — | — | — | — | -$142.7M |
| Total assets | $37.7M | $38.8M | $43.3M | $90.5M | $169.5M |
| Total liabilities | $10.8M | $11.5M | $14.0M | $55.3M | $263.1M |
| Stockholders' equity | $26.9M | $27.4M | $29.3M | $35.1M | -$93.6M |
| Cash and investments | $7.5M | $5.1M | — | $49.3M | $64.9M |
| Total debt | $6.1M | $7.2M | $8.0M | $8.8M | $197.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 12, 2026 | May 2, 2026 |
| 10-K/A | Amended annual report | Apr 1, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 30, 2026 | Mar 30, 2026 |
All 1000 TherapeuticsMD, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.